Increasingly restrictive definitions of hyperkalemia outcomes in a database study: Effect on incidence estimates

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 1, 2010, Pages 19-25

  Raebel, Marsha A ^a,b,c   Ross, Colleen ^a   Cheetham, Craig ^c,d   Petersen, Hans ^e   Saylor, Gwyn ^d   Smith, David H ^c,f   Wright, Leslie A ^a   Roblin, Douglas W ^c,f   Xu, Stanley ^a  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HMO Research Network   (United States)

^d Pharmacy Analytic Services   (United States)

^e LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^f CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Hyperkalemia; Incidence; Pharmacoepidemiology; RAAS inhibitor; Restriction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SPIRONOLACTONE;

ADULT; ADVERSE OUTCOME; ARTICLE; DIABETES MELLITUS; EMERGENCY WARD; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; HYPERKALEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; TREATMENT DURATION;

ALDOSTERONE ANTAGONISTS; AMBULATORY CARE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; HUMANS; HYPERKALEMIA; INCIDENCE; MALE; MIDDLE AGED; POTASSIUM; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 75749088515     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1882     Document Type: Article

References (32)

1. Brenner BM, Cooper ME, deZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
2. HOPE. (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
4. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, Izzo JL. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 39(suppl. 1): S94-S98.
5. Cohn JN, Tognoni G. for the Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
6. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
7. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
9. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med 1995; 332: 118-120.
10. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-677.
11. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812.
12. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol 1996; 78(8): 902-907.
13. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): 154-235.
14. Palmer BF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant 2003; 18: 1973-1975.
15. Palmer BF. Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system. N Engl J Med 2004; 351: 585-592.
16. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-551.
17. Ahuja TS, Freeman DJr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000; 20(4): 268-272.
18. Desai AS, Swedberg K, McMurray JJV, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol 2007; 50(20): 1959-1966.
19. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associate with hyperkalemia in patients with congestive heart failure. J Clin Pharm Therapeutics 2005; 30: 233-239.
20. de Denus S, Tardif J-C, White M, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J 2006; 152: 705-712.
21. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of high risk drugs at initiation of therapy in ambulatory care. J Gen Intern Med 2005; 20(12): 1120-1126.
22. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in ambulatory patients. Pharmacoepidemiol Drug Saf 2007; 16: 55-64.
23. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15: 369-386.
24. Raebel MA, Delate T, Ellis JL, Bayliss EA. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care 2008; 46: 1116-1122.
25. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995; 33(8): 783-795.
26. Maddirala S, Khan A, Vincent A, Lau K. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci 2008; 336(4): 330-335.
27. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-470.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
30. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. Arch Intern Med 1998; 158: 26-32.
31. Schneeweiss S, Avorn J. Using health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
32. Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45(10 Suppl. 2): S131-142.